


MAY 12 2006

Docket No. 31611-5A

CERTIFICATE OF FACSIMILE

I hereby certify that this paper is being transmitted via facsimile via
1-571-273-8300 and addressed to: Mail Stop Amendment,
Commissioner for Patents; P.O. Box 1450; Alexandria, VA
22313-1450 on May 12, 2006.


IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Gudmundur Johannsson et al : Paper No.:
Serial No.: 10/808,696 : Group Art Unit: 1654
Filed: March 25, 2004 : Examiner: Abdel A. Mohamed
For: **Methods for Treating a Patient Having Metabolic Syndrome**

TERMINAL DISCLAIMER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Petitioner, Pharmacia AB, a corporation organized and existing under the laws of Sweden and having a business address at SE-112 87, Stockholm, Sweden, is the owner of the entire right, title and interest in the above-identified U.S. Patent Application Serial No. 10/808,696, by virtue of an Assignment from the inventors to Pharmacia & Upjohn AB recorded on October 1, 1998 in parent application Serial No. 09/050,366 at Reel 009549, Frame 0925, and a Change of Name from Pharmacia & Upjohn AB to Pharmacia AB recorded on March 23, 2004 in parent application Serial No. 09/050,366 at Reel 015120, Frame 0409.

Petitioner is also the owner of the entire right, title and interest in U.S. Patent Application Serial No. 6,846,800 B2, by virtue of the Assignment and Change of Name referenced above.

Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent issuing on U.S. Patent Application Serial No. 10/808,696 which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §154


Application Serial No. 10/808,696
Terminal Disclaimer filed May 11, 2006

and §173, as presently shortened by any terminal disclaimer, of U.S. Patent No. 6,846,800 B2. Petitioner hereby agrees that any patent issuing on U.S. Application Serial No. 10/808,696 shall be enforceable only for and during such period that it and U.S. Patent No. 6,846,800 B2 are commonly owned. This agreement runs with any patent issuing on U.S. Application Serial No. 10/808,696 and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent issuing on U.S. Application Serial No. 10/808,696 that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 and §173 of U.S. Patent No. 6,846,800 B2, as presently shortened by any terminal disclaimer, in the event that such patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The undersigned is an attorney or agent of record. Please charge the \$130.00 fee required for filing this Terminal Disclaimer to our Visa Account. Form PTO-2038 is attached.

Respectfully submitted,


Holly D. Kozlowski
Registration No. 30,468
Dinsmore & Shohl LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

1266881